Editor - Lanhai Lü | University of Louisville | 22258

Journal of Pediatric Neurological Disorders
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Lanhai Lü

Lanhai Lü
Lanhai Lü, PhD Research Associate Department of Oral Immunology and Infectious Diseases School of Dentistry University of Louisville
University of Louisville


Lanhai Lü, PhD Research Associate Room 263C, Department of Oral Immunology and Infectious Diseases School of Dentistry University of Louisville 501 S. Preston St. Louisville, KY 40202 Tel: 502-804-6394(Cell) Email: [email protected]

Research Interest

Curent research interests Oral cancer (OC) is one of the most common cancers in the world,which accounts for about 4% of all cancer cases. Although treatments have greatly improved in the past few years, the survival rate in patients with advanced OSCC treated by surgery alone or radiotherapy alone is still poor. Chemotherapy together with surgery or radiotherapy was an effective therapy in advanced OSCC, but the effectiveness is limited by chemoresistance to certain anticancer drugs. Cisplatin has been used to treat OSCC for many years. But it often failed in some cases. The molecular mechanisms of cisplatin drug resistance remains largely known. Our present study focus on the effects of cisplatin on 𝛽-catenin, the main regulator in Wnt signaling pathway. The data shown overexpression of 𝛽-catenin could enhanced cisplatin resistance in OSCC cell lines, indicating 𝛽-catenin may play a crucial role in the development of drug resistance in OSCC(Biomed Res Int. 2016;2016:5378567.). β-catenin is a target for the ubiquitin-proteasome pathway. We also study the effects of FDA approved drug Bortezomib and another proteasome inhibitor MG132 on E-cadherin/β-catenin complex. Our data shown MG132 or bortezomib alone induced remarkable loss of cell integrity and contact, disrupted E-cadherin/β-catenin complex which could contribute to overcoming the multidrug resistance of oral cancer (Toxicol In Vitro. 2015 ;29(8):1965-76.).